Retatrutide vs Tirzepatide: Efficacy and Tolerability
Retatrutide vs tirzepatide: how to compare a triple and dual agonist across trials that weren't designed to compete. Efficacy, tolerability, and key caveats.
May 18, 2026 · 7 min read · By GLP-FAQ Editors
Retatrutide vs tirzepatide is the comparison the GLP-1 space has been building toward since tirzepatide's SURMOUNT results came in above semaglutide's STEP data. Two Eli Lilly molecules, one with two receptor targets, one with three. The question is how much the third target — the glucagon receptor — actually adds.
The short answer: the Phase 2 and emerging Phase 3 data suggests retatrutide produces more weight loss than tirzepatide, particularly at the highest doses. But the comparison requires careful handling because the two drugs have never been studied head-to-head, and the trials they each ran differ in population, duration, and era.
The Fundamental Cross-Trial Caveat
Before any number is cited, this needs to be stated plainly: retatrutide and tirzepatide have not been directly compared in a randomized controlled trial. Every comparison in this post — and in most of the coverage you'll read about these drugs — is a cross-trial comparison.
Cross-trial comparisons are useful for generating hypotheses. They're not definitive evidence. The reasons:
Different populations. Even if two trials both enrolled "adults with obesity without diabetes," the actual people enrolled may differ in ways that affect weight loss — baseline BMI, age distribution, proportion with comorbidities, geographic diversity, and treatment center characteristics.
Different protocols. Titration schedules, follow-up intensity, visit frequency, and dietary counseling vary between trials. All of these affect outcomes.
Different eras. SURMOUNT-1 enrolled in 2020–2021. Retatrutide Phase 2 enrolled in 2021–2022. Each successive cohort of obesity trial participants tends to be slightly more adherent and health-conscious than the previous one — a secular trend that's hard to control for.
Regression to the mean. Phase 2 trials have smaller samples and tighter selection criteria than Phase 3. Phase 2 results are typically more favorable than Phase 3 results for the same compound.
With those caveats explicit, here's what the data shows.
Efficacy: The Numbers Side by Side
At the highest doses in their respective trials, over comparable timeframes:
| Drug | Trial | Dose | Duration | Mean weight loss |
|---|---|---|---|---|
| Tirzepatide | SURMOUNT-1 (Phase 3) | 15 mg | 72 weeks | ~20.9% |
| Retatrutide | Phase 2 (Jastreboff 2023) | 12 mg | 48 weeks | ~24.2% |
| Retatrutide | TRIUMPH-1 (Phase 3, topline) | 12 mg | 48 weeks | Confirmed Phase 2 range |
The triple vs dual agonist gap at the highest doses is roughly 3–4 percentage points in favor of retatrutide — with the important caveat that the tirzepatide number comes from a longer-duration Phase 3 trial.
A fairer comparison looks at tirzepatide's weight loss at 48 weeks in SURMOUNT-1: approximately 18–20% depending on the dose arm. At that timeframe, the retatrutide advantage at 12 mg narrows but persists.
The dose-response is also instructive. Retatrutide produces significant weight loss even at mid-range doses — approximately 17% at 4 mg and 23% at 8 mg. The 8 mg dose compares favorably to tirzepatide 15 mg even before reaching retatrutide's 12 mg ceiling.
Responder Analysis: Who's in the High-Loss Tier
Where the retatrutide vs mounjaro comparison becomes most interesting is in the responder analysis — the proportion of participants hitting specific weight-loss thresholds.
| Weight loss threshold | SURMOUNT-1 (Tirzepatide 15 mg) | Phase 2 Retatrutide (12 mg) |
|---|---|---|
| ≥ 5% | ~96% | ~95% |
| ≥ 10% | ~90% | ~90% |
| ≥ 20% | ~56% | ~62–65% |
| ≥ 25% | ~36% | ~45–48% |
Note: these figures are approximate and drawn from published trial reports. Cross-trial comparison applies here too.
The most notable difference is at the 20%+ and 25%+ thresholds — retatrutide moves more people into what has historically been considered bariatric-surgery territory. The 5% and 10% thresholds are broadly similar.
This distribution pattern suggests retatrutide's advantage isn't just a mean shift driven by outlier responders. The high end of the distribution appears to be genuinely extended.
Mechanism: What the Third Receptor Adds
Understanding why retatrutide might outperform tirzepatide requires understanding what each receptor does.
Tirzepatide (dual agonist):
- GLP-1 agonism: appetite suppression, slower gastric emptying, glucose-dependent insulin secretion
- GIP agonism: additional appetite suppression via a different neural pathway, fat storage regulation, complementary insulin secretion, possibly improved tolerability at matched doses
Retatrutide (triple agonist) adds:
- Glucagon agonism: thermogenesis in brown and beige adipose tissue, direct fat mobilization (lipolysis), increased energy expenditure independent of intake
The theoretical advantage of the glucagon receptor is that it adds a "burn more" mechanism on top of tirzepatide's "eat less" mechanism. Weight loss on tirzepatide and semaglutide is primarily intake-reduction driven. Weight loss on retatrutide may have an additional expenditure component — meaning you're not just relying on sustained appetite suppression, but also on a raised metabolic rate.
If this distinction holds in clinical practice, it could have implications for weight loss maintenance: expenditure-based mechanisms may be more durable when drug doses are tapered or discontinued, though this is speculative.
Tolerability: The Third Receptor's Cost
The glucagon receptor doesn't add efficacy for free. Glucagon agonism has several tolerability consequences.
Nausea and vomiting. In Phase 2, retatrutide's highest-dose arms showed nausea rates of approximately 40–50% and vomiting rates higher than what's typically seen with tirzepatide at matched weight-loss doses. Glucagon receptor activation may amplify GI side effects beyond what dual-agonism produces.
Heart rate. Glucagon activates cardiac glucagon receptors and raises resting heart rate modestly. In Phase 2, increases of approximately 2–4 bpm were observed across the dose range — similar in magnitude to what's seen with some GLP-1 agents but likely driven partly by the glucagon arm. Cardiovascular outcome data from the TRIUMPH-2 trial will be essential for understanding whether this signal matters clinically.
Discontinuation rates. Phase 2 adverse-event discontinuation rates were roughly 10–16% in the 8–12 mg arms. Comparable SURMOUNT-1 rates for tirzepatide 15 mg were approximately 7–8%. The difference is meaningful.
Comparing tolerability across the two drugs at "equivalent weight-loss" doses — rather than at their respective maximum doses — is a more relevant frame for most patients. At the retatrutide dose that produces tirzepatide-equivalent weight loss (~4–8 mg), tolerability data is more favorable.
The Retatrutide vs Zepbound Comparison in Practice
For the people this comparison matters most to — those who have tried tirzepatide (Mounjaro for diabetes, Zepbound for obesity) and hit a plateau, or those starting de novo and trying to understand their options — a few practical notes:
Retatrutide is not yet FDA-approved. As of mid-2026, retatrutide remains in late-stage trials. It is not available as a branded prescription. Compounded versions circulate, but without Phase 3 approval and standardized manufacturing oversight, the risks are higher than with approved compounds.
The efficacy gap is real but uncertain in magnitude. Somewhere between 3 and 6 percentage points of additional weight loss at the highest doses is the best current estimate. Whether that translates into a clinically meaningful difference for an individual patient depends on where they are on their weight-loss journey and what they're trying to achieve.
Tolerability will vary. Some people who tolerate tirzepatide well will tolerate retatrutide well. Some won't. The titration period for retatrutide is longer and more gradual than tirzepatide's specifically to manage the higher initial side-effect load.
The better drug for you depends on what you're optimizing for. Maximum weight loss at any tolerability cost? Retatrutide data is more compelling. Best combination of weight loss and tolerability within current approved options? Tirzepatide. Both outperform semaglutide on weight loss by a significant margin.
For the deep dive on tirzepatide's Phase 3 results, see SURMOUNT trial results explained. For retatrutide's Phase 3 data specifically, TRIUMPH-1 decoded has the full breakdown.
Related reading
Free weekly newsletter
Get the GLP-1 highlights, weekly.
One short email a week — new FAQs, trial readouts, supply updates, and dosing tips. Plain-English, no spam.
Unsubscribe anytime. We never share your email.